Cybrexa and Exelixis have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12 (alphalex™ exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells … more
Separately, Cybrexa recently announced that its first in-human study of its oncology drug candidate showed evidence of effectiveness against tumors … more